Compass Therapeutics
(NASDAQ) CMPX
Compass Therapeutics Financials at a Glance
Market Cap
$367.38M
Revenue (TTM)
$0.00
Net Income (TTM)
-$68.17M
EPS (TTM)
-$0.41
P/E Ratio
-4.96
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Price
$2.05
Volume
154,617
Open
$2.09
Price
$2.05
Volume
154,617
Open
$2.09
Previous Close
$2.05
Daily Range
$2.04 - $2.12
52-Week Range
$1.61 - $6.88
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Price
$2.05
Volume
154,617
Open
$2.09
Previous Close
$2.05
Daily Range
$2.04 - $2.12
52-Week Range
$1.61 - $6.88
Estimated Earnings Date
Aug 5, 2026
CMPX News
CMPX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Compass Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
39
CEO
Thomas J. Schuetz, MD, PhD
Website
www.compasstherapeutics.comHeadquarters
Boston, MA 02135, US
CMPX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-46%
Return on Capital
-39%
Return on Assets
-33%
Earnings Yield
-20.16%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$367.38M
Shares Outstanding
180.09M
Volume
154.62K
Avg. Volume
7.45M
Financials (TTM)
Gross Profit
-$1.47M
Operating Income
-$72.84M
EBITDA
-$71.37M
Operating Cash Flow
-$49.14M
Capital Expenditure
-$25.00K
Free Cash Flow
-$49.17M
Cash & ST Invst.
$208.91M
Total Debt
$9.83M
Compass Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$368.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$367.38M
N/A
Market Cap/Employee
$10.50M
N/A
Employees
35
N/A
Net Income
-$18.32M
-10.1%
EBITDA
-$19.93M
-13.2%
Quarterly Fundamentals
Net Cash
$184.90M
+74.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$8.42M
+34.2%
Short Term Debt
$1.37M
+1159.6%
Return on Assets
-33.23%
N/A
Return on Invested Capital
-38.57%
N/A
Free Cash Flow
-$17.35M
-31.2%
Operating Cash Flow
-$17.27M
-30.7%